|
1
|
Homs MY, Voest EE and Siersema PD:
Emerging drugs for esophageal cancer. Expert Opin Emerg Drugs.
14:329–339. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stoner GD and Gupta A: Etiology and
chemoprevention of esophageal squamous cell carcinoma.
Carcinogenesis. 22:1737–1746. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mandard AM, Hainaut P and Hollstein M:
Genetic steps in the development of squamous cell carcinoma of the
esophagus. Mutat Res. 462:335–342. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Neuner G, Patel A and Suntharalingam M:
Chemoradiotherapy for esophageal cancer. Gastrointest Cancer Res.
3:57–65. 2009.PubMed/NCBI
|
|
5
|
Campbell NP and Villaflor VM: Neoadjuvant
treatment of esophageal cancer. World J Gastroenterol.
16:3793–3803. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shah MA and Kelsen DP: Combined modality
therapy of esophageal cancer: changes in the standard of care? Ann
Surg Oncol. 11:641–643. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takehana T, Kunitomo K, Suzuki S, et al:
Expression of epidermal growth factor receptor in gastric
carcinomas. Clin Gastroenterol Hepatol. 1:438–445. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ooi A, Takehana T, Li X, et al: Protein
overexpression and gene amplification of HER-2 and EGFR in
colorectal cancers: an immunohistochemical and fluorescent in situ
hybridization study. Mod Pathol. 17:895–904. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hanawa M, Suzuki S, Dobashi Y, et al: EGFR
protein overexpression and gene amplification in squamous cell
carcinomas of the esophagus. Int J Cancer. 118:1173–1180. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Normanno N, De Luca A, Bianco C, et al:
Epidermal growth factor receptor (EGFR) signaling in cancer. Gene.
366:2–16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shepard HM, Brdlik CM and Schreiber H:
Signal integration: a framework for understanding the efficacy of
therapeutics targeting the human EGFR family. J Clin Invest.
118:3574–3581. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu Y, Sheng L and Mao W: Role of epidermal
growth factor receptor tyrosine kinase inhibitors in the treatment
of esophageal carcinoma and the suggested mechanisms of action.
Oncol Lett. 5:19–24. 2013.PubMed/NCBI
|
|
13
|
Suo Z, Su W, Holm R and Nesland JM: Lack
of expression of c-erbB-2 oncoprotein in human esophageal squamous
cell carcinomas. Anticancer Res. 15:2797–2798. 1995.PubMed/NCBI
|
|
14
|
Sunpaweravong P, Sunpaweravong S,
Puttawibul P, et al: Epidermal growth factor receptor and cyclin D1
are independently amplified and overexpressed in esophageal
squamous cell carcinoma. J Cancer Res Clin Oncol. 131:111–119.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sato-Kuwabara Y, Neves JI, Fregnani JH,
Sallum RA and Soares FA: Evaluation of gene amplification and
protein expression of HER-2/neu in esophageal squamous cell
carcinoma using fluorescence in situ hybridization (FISH) and
immunohistochemistry. BMC Cancer. 9:62009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Akamatsu M, Matsumoto T, Oka K, et al:
c-erbB-2 oncoprotein expression related to chemoradioresistance in
esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys.
57:1323–1327. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gotoh M, Takiuchi H, Kawabe S, et al:
Epidermal growth factor receptor is a possible predictor of
sensitivity to chemoradiotherapy in the primary lesion of
esophageal squamous cell carcinoma. Jpn J Clin Oncol. 37:652–657.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Delektorskaya VV, Chemeris GY, Zavalishina
LE, et al: Squamous cell carcinoma of the esophagus: evaluation of
the status of epidermal growth factor receptors (EGFR and HER-2) by
immunohistochemistry and in situ hybridization. Bull Exp Biol Med.
149:615–620. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kitagawa Y, Ueda M, Ando N, Ozawa S,
Shimizu N and Kitajima M: Further evidence for prognostic
significance of epidermal growth factor receptor gene amplification
in patients with esophageal squamous cell carcinoma. Clin Cancer
Res. 2:909–914. 1996.PubMed/NCBI
|
|
20
|
Park HS, Jang MH, Kim EJ, et al: High EGFR
gene copy number predicts poor outcome in triple-negative breast
cancer. Mod Pathol. 27:1212–1222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hwangbo W, Lee JH, Ahn S, et al: EGFR gene
amplification and protein expression in invasive ductal carcinoma
of the breast. Korean J Pathol. 47:107–115. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cappuzzo F, Hirsch FR, Rossi E, et al:
Epidermal growth factor receptor gene and protein and gefitinib
sensitivity in non-small-cell lung cancer. J Natl Cancer Inst.
97:643–655. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sudo T, Mimori K, Nagahara H, et al:
Identification of EGFR mutations in esophageal cancer. Eur J Surg
Oncol. 33:44–48. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suzuki S, Dobashi Y, Sakurai H, Nishikawa
K, Hanawa M and Ooi A: Protein overexpression and gene
amplification of epidermal growth factor receptor in nonsmall cell
lung carcinomas. An immunohistochemical and fluorescence in situ
hybridization study. Cancer. 103:1265–1273. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oda K, Matsuoka Y, Funahashi A and Kitano
H: A comprehensive pathway map of epidermal growth factor receptor
signaling. Mol Syst Biol. 1:2005.0010–2005. PubMed/NCBI
|
|
27
|
Song S, Lippman SM, Zou Y, Ye X, Ajani JA
and Xu XC: Induction of cyclooxygenase-2 by benzo[a]pyrene diol
epoxide through inhibition of retinoic acid receptor-beta 2
expression. Oncogene. 24:8268–8276. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Abedi-Ardekani B, Dar NA, Mir MM, et al:
Epidermal growth factor receptor (EGFR) mutations and expression in
squamous cell carcinoma of the esophagus in central Asia. BMC
Cancer. 12:6022012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mimura K, Kono K, Hanawa M, et al:
Frequencies of HER-2/neu expression and gene amplification in
patients with oesophageal squamous cell carcinoma. Br J Cancer.
92:1253–1260. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Reichelt U, Duesedau P, Tsourlakis MCh, et
al: Frequent homogeneous HER-2 amplification in primary and
metastatic adenocarcinoma of the esophagus. Mod Pathol. 20:120–129.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37 (Suppl 4):9–15. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dreilich M, Wanders A, Brattström D, et
al: HER-2 overexpression (3+) in patients with squamous cell
esophageal carcinoma correlates with poorer survival. Dis
Esophagus. 19:224–231. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gibault L, Metges JP, Conan-Charlet V, et
al: Diffuse EGFR staining is associated with reduced overall
survival in locally advanced oesophageal squamous cell cancer. Br J
Cancer. 93:107–115. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Q, Zhu H, Xiao Z, et al: Expression
of epidermal growth factor receptor is an independent prognostic
factor for esophageal squamous cell carcinoma. World J Surg Oncol.
11:2782013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao L, He LR, Xi M, et al: Nimotuzumab
promotes radiosensitivity of EGFR-overexpression esophageal
squamous cell carcinoma cells by upregulating IGFBP-3. J Transl
Med. 10:2492012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Safran H, Suntharalingam M, Dipetrillo T,
et al: Cetuximab with concurrent chemoradiation for esophagogastric
cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys.
70:391–395. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Janmaat ML, Gallegos-Ruiz MI, Rodriguez
JA, et al: Predictive factors for outcome in a phase II study of
gefitinib in second-line treatment of advanced esophageal cancer
patients. J Clin Oncol. 24:1612–1619. 2006. View Article : Google Scholar : PubMed/NCBI
|
